Ergomed and Ferrer complete recruitment for Phase IIa insomnia clinical trial
Under Ergomed’s co-development agreement withFerrer, the Phase IIa clinical trial is a double-blind, randomised, placebo-controlled cross-over, dose finding study of two oral doses of lorediplon in adult patients with insomnia disorder.
Click on this link for more information.
